Orca Pharmaceuticals

Orca Pharmaceuticals, AstraZeneca partner to treat autoimmune disease

Wednesday, February 25, 2015

Orca Pharmaceuticals, a U.K. based biopharmaceutical company, and AstraZeneca have announced a three-year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (RORγ). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there currently is no safe, orally available and effective treatment.

[Read More]